IMR Press / FBS / Volume 1 / Issue 1 / DOI: 10.2741/S1

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Chemokines and chemokine receptors as therapeutic targets in chronic kidney disease
Show Less
1 Medizinische Poliklinik, Klinikum der Universitat Munchen, Campus Innenstadt, Ludwig-Maximilians-University, Pettenkoferstr 8a, 80336 Munich, Germany

*Author to whom correspondence should be addressed.

Academic Editor: Stephan Segerer

Front. Biosci. (Schol Ed) 2009, 1(1), 1–12;
Published: 1 June 2009

As other cytokine families, chemokines have multiple roles in local and systemic immune responses. In the kidney, the temporal and spatial expression of chemokines correlates with local renal damage. Chemokines play important roles in leukocyte trafficking and leukocyte activation, hence, blocking chemokines can effectively reduce renal leukocyte recruitment and subsequent renal damage. However, recent data indicate that blocking chemokine or chemokine receptor activity in renal disease may also exacerbate renal inflammation under certain conditions. An increasing amount of data indicate that additional roles of chemokines in the regulation of innate and adaptive immune responses may adversely affect the outcome of interventional studies. This review summarizes available in vivo studies on the blockade of chemokines and chemokine receptors in kidney diseases, with a special focus on the therapeutic potential and possible adverse effects of anti-chemokine strategies in renal inflammation.

Back to top